Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis

(2019) Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis. International Journal of Clinical Pharmacy. pp. 30-41. ISSN 2210-7703

Full text not available from this repository.

Official URL: http://apps.webofknowledge.com/InboundService.do?F...

Abstract

Background Improving the survival of patients diagnosed with metastatic colorectal cancer requires the use of chemotherapy to be managed with minimum adverse effects. Randomized control trials (RCTs) have shown promising results with a combination of bevacizumab and erlotinib to block two important tumor growth pathways, namely vascular endothelial growth factor and epidermal growth factor receptor. Aim of the Review We aimed to examine the efficacy and safety of the combination of bevacizumab and erlotinib with bevacizumab alone in the maintenance treatment of metastatic colorectal cancer, by examining PFS, OS, overall response rate (ORR), and toxicity. This study performed a systematic review meta-analysis using existing randomized clinical trial. Methods Randomized controlled trialswere systematically reviewed from PubMed, Cochrane library, SCOPUS, CRD, and Google scholar databases. After evaluating the quality of studies through the Cochrane checklist, data of the relevant studies were extracted. This meta-analysis included outcomes of overall survival, progression-free survival of the disease through the hazard ratio, and the upper and lower confidence intervals for the third and fourth degree side effects of relative risk. To perform the meta-analysis for both types of survival, two fixed and random effect models were used. Results A total of three trials, providing data of 682 patients who received maintenance treatment, were included in this meta-analysis. Conclusion The combination of bevacizumab and erlotinib significantly increased the overall survival compared to using bevacizumab alone HR=0.78, 95% CI 0.66-0.93. This combination, effectively increased progression-free survival HR=0.81, 95% CI 0.7-0.93 too. The side effects of diarrhea and grade III rash were more frequent in the group administered bevacizumab plus erlotinib. The combination of bevacizumab and erlotinib, in the maintenance treatment of metastatic colorectal cancer, significantly improved the overall survival and progression-free survival of patients, and the resulting side effects were easily treatable.

Item Type: Article
Keywords: Bevacizumab Colorectal neoplasms Erlotinib hydrochloride Maintenance chemotherapy Meta-analysis tyrosine kinase inhibitor phase-ii monoclonal-antibody maintenance therapy combination chemotherapy trial cetuximab egfr osi-774 Pharmacology & Pharmacy
Page Range: pp. 30-41
Journal or Publication Title: International Journal of Clinical Pharmacy
Journal Index: ISI
Volume: 41
Number: 1
Identification Number: https://doi.org/10.1007/s11096-018-0754-1
ISSN: 2210-7703
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/2265

Actions (login required)

View Item View Item